Wanbury Ltd

Wanbury Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 17 March 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 29 March 2026, providing investors with the latest insights into the company’s fundamentals, valuation, financial trends, and technical outlook.

At Rs 225.8, sellers were still queuing — but there were no buyers willing to take the other side. Wanbury Ltd locked at its lower circuit of 4.99% on 27 Mar 2026, with unfilled sell orders and a frozen price, reflecting persistent selling pressure in a micro-cap stock with limited liquidity.

At Rs 235.9, sellers were still queuing — but there were no buyers willing to take the other side. Wanbury Ltd locked at its lower circuit of 4.99% on 23 Mar 2026, with unfilled sell orders and a frozen price.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 17 March 2026. This shift reflects a complex interplay of technical indicators, valuation metrics, financial trends, and quality assessments, signalling caution for investors despite some positive operational performance.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 16 Mar 2026, hitting its lower circuit price limit amid intense selling pressure. The stock closed at ₹240.00, down 4.95% on the day, reflecting a maximum daily loss that underscores growing investor concerns and panic selling in the market.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a sideways trend to a mildly bearish stance. Despite a recent downgrade in daily moving averages and a 2.17% decline in the latest session, the stock’s weekly and monthly technical indicators present a complex picture, reflecting both bullish and bearish signals that investors must carefully analyse.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, surged to hit its upper circuit limit on 13 Mar 2026, propelled by robust buying interest and sustained investor enthusiasm. The stock closed at ₹257.35, marking a 5.0% gain and outperforming its sector and benchmark indices amid heightened market activity and unfilled demand.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 12 March 2026. This change reflects a nuanced improvement across multiple parameters including technical indicators, financial performance, valuation metrics, and overall quality, signalling a more balanced outlook for investors amid mixed market signals.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bearish stance to a sideways trend. Recent technical indicators reveal a complex picture with bullish signals on weekly MACD and Bollinger Bands contrasting with mildly bearish daily moving averages, signalling a period of consolidation after recent gains.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, surged to hit its upper circuit limit on 12 Mar 2026, reflecting robust investor demand and significant buying momentum despite a cautious broader market backdrop.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 4 Mar 2026, hitting its lower circuit limit as panic selling gripped investors. The stock closed at ₹241.0, down 4.87% on the day, underperforming both its sector and the broader Sensex amid sustained selling pressure and dwindling investor participation.

Wanbury Ltd, a key player in the Pharmaceuticals & Biotechnology sector, has experienced a notable shift in its technical momentum, moving from a mildly bullish to a mildly bearish stance. This transition is underscored by mixed signals from major technical indicators such as MACD, RSI, and moving averages, reflecting a complex market sentiment as the stock price declined 5.00% on 4 Mar 2026 to ₹252.85 from the previous close of ₹266.15.

Wanbury Ltd, a player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 2 March 2026. The downgrade follows a deterioration in technical indicators, persistent high debt levels, and concerns over valuation despite solid financial performance in recent quarters.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, witnessed a sharp decline on 2 Mar 2026, hitting its lower circuit limit as intense selling pressure gripped the stock. The share price plunged by 4.85%, underperforming both its sector and the broader market, amid signs of panic selling and unfilled supply weighing heavily on investor sentiment.

Wanbury Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, surged to hit its upper circuit limit on 27 Feb 2026, reflecting robust investor demand and significant buying momentum. The stock outperformed both its sector and the broader Sensex, registering a maximum daily gain of 5.54%, signalling renewed market confidence following a recent upgrade in its mojo grade.